Preliminary results of Israeli clinical trials show that fourth dose of mRNA vaccine is difficult to prevent Omicron infection

International war "epidemic" operation

On the evening of January 17, local time, Israel's "Jerusalem Post" and other media reported that the preliminary results of the world's first fourth dose of the new coronary pneumonia vaccine clinical trial conducted by the Sheba Medical Center in the country showed that the fourth dose of Pfizer was vaccinated.

The lead investigator of the clinical trial, Professor Gili Regev-Yuke, said the existing vaccine was very effective against previous strains but was less effective against the Omicron strain

As for the specific number of infected people, the level of antibodies after vaccination, and the preventive effect of the fourth vaccine on severe illness, Regev said that it is still under research and cannot be provided for the time being, and the preliminary research results are now announced

Despite the poor results of the trial, Regev believes that it may still be correct to provide a fourth dose of the vaccine to high-risk groups such as the elderly, and that the fourth dose would provide some benefits, but these benefits are not enough to justify providing it to everyone's plan

Sheba Medical Center launched the above-mentioned trial on December 27 last year, inoculating the fourth dose of Pfizer's vaccine to 150 medical staff who had received the third dose for more than 4 months and had serum antibody levels below 700

In early January, Regev had said that a week after the fourth dose, antibody levels had increased fivefold

At present, Israel is providing the fourth dose of the new crown vaccine for people over 60 years old, immunocompromised and medical staff, and nearly 540,000 people have been vaccinated nationwide